@maciejbanach Nice to see more real-world data on inclisiran. We had similar findings in ~150 pt.: PCSK9 man therapy associated w/less profound LDL-C response, even though the majority had 3 months between two drugs
https://t.co/DdsQEbBqyv
1) there is a high variability in LDL-C reduction between individuals 2) statin/eze use is associated with greater LDL-C reduction 3) LDL-C reduction was less pronounced in those who were switched from antibody to siRNA (even with 3 months wash-out)
https://t.co/DdsQEbBqyv
Jeden Sonntag neu: Medizinische Fakten, spannende Einblicke hinter die Kulissen des Klinikums und eine Menge Unterhaltung. Die @Uniklinik_Fr startet auf #Youtube durch. Jetzt reinschauen: https://t.co/avBQNM1UdN #Medizinwissen
In our study,almost 40% of patients with STEMI achieve LDL target levels already at hospital discharge and 80% at FU w.station+ezetimibe.20% need further therapy escalation.We can & have to get better in secondary prevention in our clinical practice. https://t.co/JsrzM5FLL8